scholarly journals Evaluation of the peripheral dose in stereotactic radiotherapy and radiosurgery treatmentsa)

2010 ◽  
Vol 37 (7Part1) ◽  
pp. 3587-3594 ◽  
Author(s):  
Erika Di Betta ◽  
Laura Fariselli ◽  
Achille Bergantin ◽  
Federica Locatelli ◽  
Antonella Del Vecchio ◽  
...  
Keyword(s):  
Stereotactic Radiotherapy ◽  
Peripheral Dose

scholarly journals Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Megumi Uto ◽  
Kengo Ogura ◽  
Tomohiro Katagiri ◽  
Keiichi Takehana ◽  
Takashi Mizowaki
Keyword(s):  
Brain Metastases ◽  
Stereotactic Radiotherapy ◽  
Target Volume ◽  
Good Prognosis ◽  
Adaptive Radiotherapy ◽  
Mri Scan ◽  
Peripheral Dose ◽  
Conventional Radiotherapy ◽  
Dynamic Conformal Arc Therapy ◽  
Magnetic Resonance Imaging Mri

Abstract Background The risk for radiation necrosis is lower in fractionated stereotactic radiotherapy (SRT) than in conventional radiotherapy, and 13-fraction SRT is our method of choice for the treatment of brain metastases ≥ around 2 cm or patients who are expected to have a good prognosis. As 13-fraction SRT lasts for at least 17 days, adaptive radiotherapy based on contrast-enhanced mid-treatment magnetic resonance imaging (MRI) is often necessary for patients undergoing 13-fraction SRT. In this study, we retrospectively analyzed interfractional target changes in patients with brain metastases treated with 13-fraction SRT. Methods Our analyses included data from 23 patients and 27 metastatic brain lesions treated with 13-fraction SRT with dynamic conformal arc therapy. The peripheral dose prescribed to the planning target volume (PTV) was 39–44.2 Gy in 13-fractions. The gross tumor volume (GTV) of the initial SRT plan (initial GTV), initial PTV, and modified GTV based on the mid-treatment MRI scan (mid-treatment GTV) were assessed. Results The median initial GTV was 3.8 cm3 and the median time from SRT initiation to the mid-treatment MRI scan was 6 days. Compared to the initial GTV, the mid-treatment GTV increased by more than 20% in five lesions and decreased by more than 20% in five lesions. Interfractional GTV volume changes of more than 20% were not significantly associated with primary disease or the presence of cystic components/necrosis. The mid-treatment GTV did not overlap perfectly with the initial PTV in more than half of the lesions. Conclusions Compared to the initial GTV, the mid-treatment GTV changed by more than 20% in almost one-third of lesions treated with 13-fraction SRT. As SRT usually generates a steep dose gradient as well as increasing the maximum dose of PTV compared to conventional radiotherapy, assessment of the volume and locational target changes and adaptive radiotherapy should be considered as the number of fractions increases.

Hypofractionated Stereotactic Radiotherapy for Vestibular Schwannoma

Skull Base ◽  
2009 ◽  
Vol 19 (01) ◽  
Author(s):  
Rutger Balvers ◽  
Bianca Rijken ◽  
Alexandra Romero ◽  
Anne Linge ◽  
A.H.G. Dallenga ◽  
...  
Keyword(s):  
Vestibular Schwannoma ◽  
Stereotactic Radiotherapy ◽  
Hypofractionated Stereotactic Radiotherapy
Sign in / Sign up

Export Citation Format

Share Document